Bicara Therapeutics (BCAX) Competitors $9.07 -0.13 (-1.37%) Closing price 07/3/2025 01:34 PM EasternExtended Trading$9.17 +0.10 (+1.10%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BCAX vs. IRON, BLTE, IDYA, HRMY, ADPT, SPRY, CNTA, TARS, BEAM, and SRPTShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Disc Medicine (IRON), Belite Bio (BLTE), IDEAYA Biosciences (IDYA), Harmony Biosciences (HRMY), Adaptive Biotechnologies (ADPT), ARS Pharmaceuticals (SPRY), Centessa Pharmaceuticals (CNTA), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Its Competitors Disc Medicine Belite Bio IDEAYA Biosciences Harmony Biosciences Adaptive Biotechnologies ARS Pharmaceuticals Centessa Pharmaceuticals Tarsus Pharmaceuticals Beam Therapeutics Sarepta Therapeutics Disc Medicine (NASDAQ:IRON) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership. Is IRON or BCAX more profitable? Bicara Therapeutics' return on equity of 0.00% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -22.61% -21.07% Bicara Therapeutics N/A N/A N/A Do institutionals and insiders have more ownership in IRON or BCAX? 83.7% of Disc Medicine shares are held by institutional investors. 4.2% of Disc Medicine shares are held by company insiders. Comparatively, 15.5% of Bicara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings and valuation, IRON or BCAX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$109.36M-$3.92-13.97Bicara TherapeuticsN/AN/A-$68MN/AN/A Does the media favor IRON or BCAX? In the previous week, Disc Medicine had 7 more articles in the media than Bicara Therapeutics. MarketBeat recorded 8 mentions for Disc Medicine and 1 mentions for Bicara Therapeutics. Disc Medicine's average media sentiment score of 0.41 beat Bicara Therapeutics' score of 0.00 indicating that Disc Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend IRON or BCAX? Disc Medicine currently has a consensus price target of $96.70, indicating a potential upside of 76.64%. Bicara Therapeutics has a consensus price target of $31.86, indicating a potential upside of 251.10%. Given Bicara Therapeutics' higher probable upside, analysts clearly believe Bicara Therapeutics is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Bicara Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryDisc Medicine and Bicara Therapeutics tied by winning 5 of the 10 factors compared between the two stocks. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$492.46M$2.91B$5.56B$9.03BDividend YieldN/A2.44%5.22%3.99%P/E RatioN/A21.5627.6920.25Price / SalesN/A245.33413.82173.23Price / CashN/A42.7336.8958.10Price / Book1.007.518.035.67Net Income-$68M-$55.14M$3.18B$249.21M7 Day Performance4.18%4.61%2.93%3.28%1 Month Performance-21.10%0.90%1.72%3.95%1 Year PerformanceN/A5.40%34.39%20.98% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara Therapeutics1.3923 of 5 stars$9.07-1.4%$31.86+251.1%N/A$492.46MN/A0.0032IRONDisc Medicine3.0359 of 5 stars$52.96-2.8%$96.70+82.6%+17.4%$1.89BN/A-13.5130News CoverageAnalyst ForecastBLTEBelite Bio2.4505 of 5 stars$57.70-2.3%$96.67+67.5%+31.3%$1.88BN/A-42.4310News CoverageAnalyst ForecastGap UpIDYAIDEAYA Biosciences3.4697 of 5 stars$21.02-1.6%$53.42+154.1%-35.5%$1.87B$7M-5.8680HRMYHarmony Biosciences4.795 of 5 stars$31.60-1.2%$53.63+69.7%+1.0%$1.84B$714.73M12.06200Positive NewsADPTAdaptive Biotechnologies3.317 of 5 stars$11.65-1.2%$10.57-9.3%+238.3%$1.79B$178.96M-12.14790News CoverageSPRYARS Pharmaceuticals3.2381 of 5 stars$17.45-4.1%$31.00+77.7%+81.2%$1.79B$89.15M-109.0690Insider TradeHigh Trading VolumeCNTACentessa Pharmaceuticals3.1642 of 5 stars$13.14+0.1%$27.89+112.2%+64.0%$1.75B$6.85M-7.26200TARSTarsus Pharmaceuticals2.0769 of 5 stars$40.51+0.4%$66.67+64.6%+47.3%$1.70B$182.95M-14.8450Positive NewsBEAMBeam Therapeutics2.5203 of 5 stars$17.01+1.3%$48.75+186.6%-13.3%$1.69B$63.52M-3.69510SRPTSarepta Therapeutics4.7382 of 5 stars$17.10-0.1%$60.88+256.0%-88.0%$1.68B$1.90B-6.361,372Trending NewsHigh Trading Volume Related Companies and Tools Related Companies IRON Competitors BLTE Competitors IDYA Competitors HRMY Competitors ADPT Competitors SPRY Competitors CNTA Competitors TARS Competitors BEAM Competitors SRPT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
